Clinical Trials on Syringotropic Mycosis Fungoides

Total 7539 results

Rochester Skin Lymphoma Medical Group, PLLC
Rochester General Hospital

Completed

Mechlorethamine Induced Contact Dermatitis Avoidance Study (MIDAS)

Mycosis Fungoides | Cutaneous T-cell Lymphoma | Transformed Mycosis Fungoides | Cutaneous T-cell Lymphoma Stage I | Folliculotropic Mycosis Fungoides | Granulomatous Slack Skin | Syringotropic Mycosis Fungoides | Mycosis Fungoides Variant

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Stage I Mycosis Fungoides | Stage II Mycosis Fungoides | Stage III Mycosis Fungoides

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Recurrent Mycosis Fungoides... and other conditions

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Recurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Transformed Mycosis Fungoides | Folliculotropic... and other conditions

United States
Northwestern University
Amgen

Terminated

Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Mycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary Syndrome | Sézary | Advanced Mycosis Fungoides

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Withdrawn

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma

Recurrent Mycosis Fungoides and Sezary Syndrome | Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IIB Mycosis Fungoides and Sezary Syndrome | Stage IIIA Mycosis Fungoides and Sezary Syndrome | Stage IIIB Mycosis Fungoides and Sezary Syndrome | Stage IVA Mycosis Fungoides and Sezary Syndrome | Stage...
National Cancer Institute (NCI)

Completed

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Recurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides

Refractory Mycosis Fungoides

United States
National Cancer Institute (NCI)

Recruiting

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8

United States
Medical University of Graz

Completed

PUVA Maintenance Therapy in Mycosis Fungoides (M_PUVA_2012)

Patch/Plaque Stage Mycosis Fungoides

Austria
Kevin Cooper MD
National Cancer Institute (NCI)

Completed

Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage IB Mycosis Fungoides/Sezary Syndrome | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IIA Mycosis...

United States
European Organisation for Research and Treatment...
Hoffmann-La Roche

Terminated

PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) (PARCT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Spain, Switzerland
City of Hope Medical Center

Withdrawn

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Sezary Syndrome | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Folliculotropic Mycosis Fungoides | CD30-Positive Neoplastic Cells Present | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
Kyowa Kirin Pharmaceutical Development Ltd

Recruiting

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) (PROSPER)

Mycosis Fungoides and Sézary Syndrome

Spain, United Kingdom, Netherlands, United States, Italy
Medical University of Vienna

Recruiting

Diagnostic Classifier for Cutaneous T-cell Lymphomas

CTCL/ Mycosis Fungoides

Austria
European Organisation for Research and Treatment...
Mallinckrodt

Withdrawn

Study of Photopheresis in the Treatment of Erythrodermic MF and SS (PROMPT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Switzerland
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; MorphoSys AG; Swim Across America; Daniel...

Recruiting

Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome

Mycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary Syndrome

United States
OncoSec Medical Incorporated

Terminated

Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma (CTCL)

Mycosis Fungoides (MF) | Cutaneous T Cell Lymphomas (CTCL)

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditions

United States
Northwestern University
National Cancer Institute (NCI); Celgene

Active, not recruiting

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous... and other conditions

United States
Soligenix

Recruiting

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States
Madrilenian Group of Cutaneous Lymphomas

Terminated

PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides (MF99)

Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Spain
Soligenix

Completed

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States
Moleculin Biotech, Inc.

Completed

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Poland
miRagen Therapeutics, Inc.

Terminated

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study (PRISM)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States, France, Belgium
Innate Pharma

Active, not recruiting

IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK)

Lymphoma, T-Cell | Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

United States, Spain, France, Italy, Belgium, Austria, Germany, Poland
miRagen Therapeutics, Inc.

Terminated

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States, France, Spain, Canada, United Kingdom, Australia, Italy, Belgium
Istanbul Training and Research Hospital

Completed

Dermoscopic Findings of Small Plaque Parapsoriasis and Patch Stage Mycosis Fungoides and Histopathological Correlation

Mycosis Fungoides of Skin

Turkey
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Sezary Syndrome | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Folliculotropic Mycosis Fungoides | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous...

United States
Affimed GmbH

Completed

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

Peripheral T Cell Lymphoma | Transformed Mycosis Fungoides

Spain, United States, Korea, Republic of, Italy, France, Australia, Germany, Poland, Turkey, Russian Federation
Case Comprehensive Cancer Center

Not yet recruiting

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Lymphoma, Follicular | Cutaneous T-cell Lymphoma | Non Hodgkin Lymphoma | Lymphoma, Large-Cell, Anaplastic | Lymphomatoid Papulosis | Mycosis Fungoides of Skin (Diagnosis)

United States
National Cancer Institute (NCI)

Completed

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7

United States
University College, London
Merck Sharp & Dohme LLC

Active, not recruiting

A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT)

Cutaneous T Cell Lymphoma | Mycosis Fungoides/Sezary Syndrome

United Kingdom
European Organisation for Research and Treatment...

Terminated

REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (REACH)

Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)

France
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (FIL_MOGA)

Cutaneous T Cell Lymphoma | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Cutaneous T-Cell Lymphoma/Sezary Syndrome

Italy
National Cancer Institute (NCI)

Completed

506U78 in Treating Patients With Lymphoma

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Small Intestine Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis... and other conditions

United States
Northwestern University

Recruiting

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

Mycosis Fungoides

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Actelion

Withdrawn

Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides

Mycosis Fungoides

United States
Stanford University
National Institutes of Health (NIH)

Withdrawn

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

Mycosis Fungoides
Angimmune LLC
University of Colorado, Denver; Washington University School of Medicine; Yale... and other collaborators

Unknown

Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides (Resimmune®)

Mycosis Fungoides
M.D. Anderson Cancer Center

Completed

Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

Lymphoma

United States
Yaupon Therapeutics

Completed

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

Mycosis Fungoides

United States
National and Kapodistrian University of Athens
Recordati Rare Diseases

Recruiting

The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients (GR-CTCL_CL)

Mycosis Fungoides

Greece
Bezmialem Vakif University

Recruiting

Histopathological Changes in Mycosis Fungoides

Mycosis Fungoides

Turkey
Cairo University

Recruiting

Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study

Mycosis Fungoides

Egypt
M.D. Anderson Cancer Center
Seagen Inc.

Recruiting

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Mycosis Fungoides

United States
Indiana University
Purdue University

Terminated

Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides (BDI)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides

United States

Clinical Trials on Syringotropic Mycosis Fungoides

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations